5 questions facing emerging biotech in 2023
Bio Pharma Dive
JANUARY 10, 2023
Investors expect another lackluster year in IPOs, while company restructurings look set to continue as biotech executives try to conserve cash
Sat.Jan 07, 2023 - Fri.Jan 13, 2023
271 
Health Canada gives approval to Enhertu for breast cancer treatment
Pharmaceutical Technology
JANUARY 13, 2023
Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
A Holiday Surprise; FTC Published Its Health Products Compliance Guidance
The FDA Law Blog
JANUARY 10, 2023
By Riëtte van Laack & Ricardo Carvajal — On Dec. 20, 2022, FTC announced the publication of its Health Products Compliance Guidance (“new Guidance”).
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
The Pharma Data
JANUARY 9, 2023
Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome’s Discovery Engine – Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
5 FDA decisions to watch in the first quarter
Bio Pharma Dive
JANUARY 9, 2023
An Alzheimer’s drug from Eli Lilly, BioMarin’s hemophilia gene therapy and a new type of breast cancer treatment are among the top decisions on the agency’s docket through the end of March
Are we entering the era of biologics for COPD?
Pharmaceutical Technology
JANUARY 8, 2023
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
JPM23, Day 1: BMS touts new launches as patent cliff looms; Regeneron's Eylea sales disappoint
Fierce Pharma
JANUARY 9, 2023
JPM23, Day 1: BMS touts new launches as patent cliff looms; Regeneron's Eylea sales disappoint. esagonowsky. Mon, 01/09/2023 - 09:55
5 questions facing gene therapy in 2023
Bio Pharma Dive
JANUARY 12, 2023
Buoyed by recent approvals, the field faces a pivotal year that’s likely to bring new treatments as well as more challenges
Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
Pharmaceutical Technology
JANUARY 10, 2023
On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D).
AstraZeneca's Tezspire receives approval for asthma treatment
Pharma Times
JANUARY 13, 2023
Green light for new asthma pen which offers self-administration option across the EU
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
BioNTech to acquire AI specialist InstaDeep: ‘Our aim is to be a technology company where AI is seamlessly integrated into all aspects of our work’
BioPharma Reporter
JANUARY 10, 2023
German mRNA pioneer BioNTech will acquire InstaDeep, an artificial intelligence and machine learning specialist, for around Â362m ($439m): pledging to incorporate rapidly evolving AI capabilities into its research, drug discovery, manufacturing and deployment processes. Bio Developments
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Bio Pharma Dive
JANUARY 10, 2023
The FDA commissioner shared advice for drugmakers at the J.P. Morgan Healthcare conference, while venture investors cautioned of a coming funding crunch for young biotechs
AstraZeneca starts 2023 with $1.8 billion cardiovascular acquisition
Pharmaceutical Technology
JANUARY 10, 2023
AstraZeneca has announced its plans to acquire US-based biopharmaceutical company CinCor in a $1.8 billion deal, signalling the company’s interest in renal and cardiovascular therapies. Last August, CinCor Pharma raised $258.7
Pheno and UCB reveal neurodegenerative disease programme agreement
Pharma Times
JANUARY 11, 2023
Global preclinical programme has the potential for disease modifying therapeutics
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says
Fierce Pharma
JANUARY 10, 2023
JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says. esagonowsky. Tue, 01/10/2023 - 08:51
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Bio Pharma Dive
JANUARY 11, 2023
Executives at the two pharmas talked up their rival autoimmune disease drugs at the J.P. Morgan Healthcare Conference, while Prime Medicine’s CEO pondered a busy future
US FDA approves Eisai-Biogen’s antibody for Alzheimer’s
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD).
SIFI and Avanzanite announce AKANTIOR agreement
Pharma Times
JANUARY 10, 2023
Partnership offers treatment access to hundreds of patients across several European countries
JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amyrt buyout
Fierce Pharma
JANUARY 9, 2023
JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amyrt buyout. esagonowsky. Mon, 01/09/2023 - 08:14
5 questions facing the pharma industry in 2023
Bio Pharma Dive
JANUARY 9, 2023
Drug price reforms and regulatory scrutiny present challenges for large drugmakers, although successes in Alzheimer’s and obesity have brought new opportunities, too
AstraZeneca to buy US-based CinCor Pharma for $1.8bn
Pharmaceutical Technology
JANUARY 10, 2023
AstraZeneca has signed a definitive agreement to buy US-based biopharmaceutical company CinCor Pharma in a deal valued at about $1.8bn. Under the deal, the company will initiate a tender offer to purchase all the outstanding shares of CinCor Pharma for $26 per share in cash.
AstraZeneca makes CinCor Pharma acquisition
Pharma Times
JANUARY 9, 2023
Agreement involves access to global rights of blood pressure lowering therapy baxdrostat
Bayer taps Google’s quantum power for drug discovery
Pharma Phorum
JANUARY 12, 2023
Bayer has signed an agreement with Google aimed at using high-level processing power to handle quantum chemistry calculations used to predict the chemical and physical properties of drug molecules at the atomic scale.
AstraZeneca, Avillion get FDA approval for new ‘rescue’ drug for asthma
Bio Pharma Dive
JANUARY 11, 2023
Airsupra joins a growing portfolio of new drugs that are helping the British drugmaker offset wilting sales of older respiratory medicines like Pulmicort
BioNTech to buy UK-based AI company InstaDeep
Pharmaceutical Technology
JANUARY 11, 2023
BioNTech has signed an agreement to buy UK-based artificial intelligence (AI) and machine learning (ML)-based products developer InstaDeep in a deal valued at about $440m (£362m) in cash and shares.
Artificial pancreas technology set to change lives
Pharma Times
JANUARY 10, 2023
Emerging technology could help patients who are unable to manage their type 1 diabetes
JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023
Fierce Pharma
JANUARY 9, 2023
JPM23: Moderna reaped $18.4B in COVID vaccine sales last year, projects at least $5B in 2023. kdunleavy. Mon, 01/09/2023 - 10:34
Sanofi tops off venture arm, bringing fund to $750M
Bio Pharma Dive
JANUARY 12, 2023
The pharma is rolling out a multi-year capital commitment to its biotech investment group, which this week backed biotech NextPoint Therapeutics
BARDA awards contract for Sabin’s Ebola Sudan and Marburg virus vaccines
Pharmaceutical Technology
JANUARY 13, 2023
The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.
AlzeCure begins Alzheimer's therapy development phase
Pharma Times
JANUARY 11, 2023
Candidate will go through the development programme, which includes safety and tolerability studies
AI and the Big Data paradigm – big ambitions in novel drug discovery
Pharma Phorum
JANUARY 11, 2023
Over the past few decades, data generation has veritably exploded. However, the ‘Big Data paradigm’ is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information.
HHS lays out timing for drug price negotiations
Bio Pharma Dive
JANUARY 11, 2023
The agency will kick off discussions on how it will negotiate Medicare drug prices in the spring and publish a list of the first 10 drugs selected by Sept. 1, 2023
AbbVie and Anima partner for mRNA biology modulators
Pharmaceutical Technology
JANUARY 11, 2023
AbbVie has collaborated with Anima Biotech for the discovery and development of mRNA biology modulators against three oncology and immunology targets.
NHS Confederation responds to Prime Minister’s promise of NHS support
Pharma Times
JANUARY 9, 2023
New financial assistance emerges as UK Government announces imminent discharge fund
Let's personalize your content